Evaluation of Atracurium in Anaesthetized Man
Overview
Affiliations
Atracurium is a potent competitive neuromuscular blocking agent in anesthetized man with no cardiovascular effects at doses required for paralysis. Endotracheal intubation can be accomplished after i.v. doses of 0.6 and 0.3 mg kg-1, within 1 and 2 min respectively. Paralysis is readily antagonized by neostigmine and is enhanced by halothane. The consistent response in terms of block and recovery which emerged when the drug was given as increments of 0.05 or 0.1 mg kg-1 indicates the absence of cumulative effects. The course of action of atracurium was appreciably shorter than that of other recognized competitive blocking agents. Doses of 0.3--0.6 mg kg-1 i.v. provided adequate relaxation during surgical intervention for 15--45 min; spontaneous recovery without the use of neostigmine was observed in some patients. In addition to the non-enzymic decomposition by "Hofmann Elimination", atracurium may also undergo an enzymic ester hydrolysis but, unlike suxamethonium, it may not be destroyed by pseudocholinesterase.
Kissin I Drug Des Devel Ther. 2021; 15:2495-2505.
PMID: 34149285 PMC: 8205612. DOI: 10.2147/DDDT.S316636.
Comparison of sensitivity of neuromuscular monitoring tests: twitch versus tetanic test.
Tripathi M, Singh P, Ambesh S, Kaushik S J Anesth. 2017; 11(4):245-249.
PMID: 28921060 DOI: 10.1007/BF02480738.
Hsieh W, Huang H, Peng S, Liang J, Leung C, Yeh G Eur J Pediatr. 2006; 165(6):361-6.
PMID: 16429277 DOI: 10.1007/s00431-005-0063-2.
The cardiovascular effects of atracurium and it's metabolite.
Fukushima K, Aoki T, Watanabe K, Satoh T, Nagashima H J Anesth. 1990; 4(1):45-50.
PMID: 15236016 DOI: 10.1007/s0054000040045.
Booij L Pharm World Sci. 1997; 19(1):1-12.
PMID: 9089749 DOI: 10.1023/a:1008694726564.